FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103756025> ?p ?o ?g. }

• W2103756025 endingPage "446" @default.
• W2103756025 startingPage "441" @default.
• W2103756025 abstract "<h3>Background</h3> Patients with non-resectable glioblastoma generally exhibit a poor prognosis, even after radiotherapy plus concomitant and adjuvant temozolomide (XRT/TMZ→TMZ). Unfortunately, no data are available concerning the predictive value of O⁶-methylguanine-DNA methyltransferase (MGMT) promoter methylation for this important subpopulation. For clarification, a prospective study was conducted. <h3>Methods</h3> Adult patients with a non-resectable glioblastoma were included. A molecular stereotactic biopsy technique was used for tumour characterisation combining histopathological diagnosis with small sample size adjusted methylation-specific PCR (MSP) and sodium bisulfite sequencing. Treatment included XRT (60 Gy in 30 fractions)/TMZ (daily dose of 75 mg/m²)→TMZ (150–200 mg/m² per day for 5 days of every28-day cycle). The primary end point was progression-free survival (PFS). Secondary endpoints were overall survival (OS) and treatment response (TR). Patients were categorised in the Radiation Therapy Oncology Group (RTOG)-recursive partitioning analysis (RPA) Classes III (N=4), IV (N=12), V (N=28) and VI (N=12). <h3>Results and discussion</h3> The success rates of MSP and sequence analyses were 100%. The <i>MGMT</i> promoter was methylated in 30/56 tumours, which was associated with an increased PFS (median 56 versus 20 weeks; hazard ratio 0.15; range 0.07 to 0.33; p<0.0001), higher frequency of TR (93.3% vs 46.2%; p=0.0008) and increased OS (median 104 vs 28 weeks; hazard ratio 0.18; range 0.08 to 0.38; p<0.0001). The transient perioperative morbidity was 1.8%. <h3>Conclusion</h3> <i>MGMT</i> promoter methylation has a predominant favourable influence even for the important subpopulation with non-resectable glioblastoma. The molecular stereotactic biopsy technique is safe and effective for predictive evaluation and helps to avoid both over- and undertreatment." @default.
• W2103756025 created "2016-06-24" @default.
• W2103756025 creator A5002641481 @default.
• W2103756025 creator A5005815307 @default.
• W2103756025 creator A5017129868 @default.
• W2103756025 creator A5038323479 @default.
• W2103756025 creator A5040282784 @default.
• W2103756025 creator A5050502610 @default.
• W2103756025 creator A5062781311 @default.
• W2103756025 creator A5063272226 @default.
• W2103756025 creator A5074844284 @default.
• W2103756025 creator A5076447443 @default.
• W2103756025 date "2010-09-22" @default.
• W2103756025 modified "2023-09-25" @default.
• W2103756025 title "Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide" @default.
• W2103756025 cites W1560814177 @default.
• W2103756025 cites W1895931341 @default.
• W2103756025 cites W1959628099 @default.
• W2103756025 cites W1965583321 @default.
• W2103756025 cites W1979273476 @default.
• W2103756025 cites W1985200173 @default.
• W2103756025 cites W1994769053 @default.
• W2103756025 cites W2001660159 @default.
• W2103756025 cites W2036044314 @default.
• W2103756025 cites W2059624809 @default.
• W2103756025 cites W2074242592 @default.
• W2103756025 cites W2074861436 @default.
• W2103756025 cites W2076234267 @default.
• W2103756025 cites W2096287682 @default.
• W2103756025 cites W2102381549 @default.
• W2103756025 cites W2105100844 @default.
• W2103756025 cites W2112014411 @default.
• W2103756025 cites W2146803439 @default.
• W2103756025 cites W2155524619 @default.
• W2103756025 cites W2158681922 @default.
• W2103756025 cites W2160382843 @default.
• W2103756025 cites W2328946792 @default.
• W2103756025 cites W3041047318 @default.
• W2103756025 doi "https://doi.org/10.1136/jnnp.2010.214593" @default.
• W2103756025 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20861061" @default.
• W2103756025 hasPublicationYear "2010" @default.
• W2103756025 type Work @default.
• W2103756025 sameAs 2103756025 @default.
• W2103756025 citedByCount "45" @default.
• W2103756025 countsByYear W21037560252012 @default.
• W2103756025 countsByYear W21037560252013 @default.
• W2103756025 countsByYear W21037560252014 @default.
• W2103756025 countsByYear W21037560252015 @default.
• W2103756025 countsByYear W21037560252016 @default.
• W2103756025 countsByYear W21037560252017 @default.
• W2103756025 countsByYear W21037560252018 @default.
• W2103756025 countsByYear W21037560252019 @default.
• W2103756025 countsByYear W21037560252020 @default.
• W2103756025 countsByYear W21037560252021 @default.
• W2103756025 countsByYear W21037560252022 @default.
• W2103756025 countsByYear W21037560252023 @default.
• W2103756025 crossrefType "journal-article" @default.
• W2103756025 hasAuthorship W2103756025A5002641481 @default.
• W2103756025 hasAuthorship W2103756025A5005815307 @default.
• W2103756025 hasAuthorship W2103756025A5017129868 @default.
• W2103756025 hasAuthorship W2103756025A5038323479 @default.
• W2103756025 hasAuthorship W2103756025A5040282784 @default.
• W2103756025 hasAuthorship W2103756025A5050502610 @default.
• W2103756025 hasAuthorship W2103756025A5062781311 @default.
• W2103756025 hasAuthorship W2103756025A5063272226 @default.
• W2103756025 hasAuthorship W2103756025A5074844284 @default.
• W2103756025 hasAuthorship W2103756025A5076447443 @default.
• W2103756025 hasBestOaLocation W21037560252 @default.
• W2103756025 hasConcept C104317684 @default.
• W2103756025 hasConcept C126322002 @default.
• W2103756025 hasConcept C126894567 @default.
• W2103756025 hasConcept C143998085 @default.
• W2103756025 hasConcept C207103383 @default.
• W2103756025 hasConcept C2777389519 @default.
• W2103756025 hasConcept C2778424827 @default.
• W2103756025 hasConcept C2779384505 @default.
• W2103756025 hasConcept C2989005 @default.
• W2103756025 hasConcept C33288867 @default.
• W2103756025 hasConcept C44249647 @default.
• W2103756025 hasConcept C509974204 @default.
• W2103756025 hasConcept C55493867 @default.
• W2103756025 hasConcept C71924100 @default.
• W2103756025 hasConcept C86803240 @default.
• W2103756025 hasConcept C90924648 @default.
• W2103756025 hasConcept C91965660 @default.
• W2103756025 hasConceptScore W2103756025C104317684 @default.
• W2103756025 hasConceptScore W2103756025C126322002 @default.
• W2103756025 hasConceptScore W2103756025C126894567 @default.
• W2103756025 hasConceptScore W2103756025C143998085 @default.
• W2103756025 hasConceptScore W2103756025C207103383 @default.
• W2103756025 hasConceptScore W2103756025C2777389519 @default.
• W2103756025 hasConceptScore W2103756025C2778424827 @default.
• W2103756025 hasConceptScore W2103756025C2779384505 @default.
• W2103756025 hasConceptScore W2103756025C2989005 @default.
• W2103756025 hasConceptScore W2103756025C33288867 @default.
• W2103756025 hasConceptScore W2103756025C44249647 @default.
• W2103756025 hasConceptScore W2103756025C509974204 @default.
• W2103756025 hasConceptScore W2103756025C55493867 @default.

• next